Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C86H116N16O12S4 |
Molecular Weight | 1694.2089 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 15 / 15 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCN1C[C@@]([H])(C[C@]2([H])c3cccc4c3c(C[C@]21[H])c[nH]4)CSCC(=NCCCC[C@]([H])(C(=N[C@@]5([H])CSSC[C@@]([H])(C(=N[C@@]([H])([C@@]([H])(C)O)C(=N)O)O)N=C([C@]([H])(CC)N=C([C@]([H])(CCCCN)N=C([C@@]([H])(Cc6c[nH]c7ccccc67)N=C([C@]([H])(Cc8ccc(cc8)O)N=C5O)O)O)O)O)O)N=C(CSC[C@]9([H])C[C@]%10([H])c%11cccc%12c%11c(C[C@@]%10([H])N(CCC)C9)c[nH]%12)O)O
InChI
InChIKey=WLBJBODHTIKYSL-JFPOTJHNSA-N
InChI=1S/C86H116N16O12S4/c1-5-30-101-41-51(32-60-58-17-14-22-64-76(58)54(39-91-64)36-72(60)101)43-115-47-74(105)89-29-13-11-21-66(93-75(106)48-116-44-52-33-61-59-18-15-23-65-77(59)55(40-92-65)37-73(61)102(42-52)31-6-2)81(109)99-70-45-117-118-46-71(86(114)100-78(49(4)103)79(88)107)98-80(108)62(7-3)94-82(110)67(20-10-12-28-87)95-84(112)69(35-53-38-90-63-19-9-8-16-57(53)63)97-83(111)68(96-85(70)113)34-50-24-26-56(104)27-25-50/h8-9,14-19,22-27,38-40,49,51-52,60-62,66-73,78,90-92,103-104H,5-7,10-13,20-21,28-37,41-48,87H2,1-4H3,(H2,88,107)(H,89,105)(H,93,106)(H,94,110)(H,95,112)(H,96,113)(H,97,111)(H,98,108)(H,99,109)(H,100,114)/t49-,51-,52-,60-,61-,62+,66-,67+,68+,69-,70+,71+,72-,73-,78+/m1/s1
Molecular Formula | C86H116N16O12S4 |
Molecular Weight | 1694.2089 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 15 / 15 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Jun 25 20:50:01 UTC 2021
by
admin
on
Fri Jun 25 20:50:01 UTC 2021
|
Record UNII |
L32IM11DV4
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
11439
Created by
admin on Fri Jun 25 20:50:02 UTC 2021 , Edited by admin on Fri Jun 25 20:50:02 UTC 2021
|
PRIMARY | INN | ||
|
778630-77-6
Created by
admin on Fri Jun 25 20:50:02 UTC 2021 , Edited by admin on Fri Jun 25 20:50:02 UTC 2021
|
PRIMARY | |||
|
868562-36-1
Created by
admin on Fri Jun 25 20:50:02 UTC 2021 , Edited by admin on Fri Jun 25 20:50:02 UTC 2021
|
PRIMARY | |||
|
L32IM11DV4
Created by
admin on Fri Jun 25 20:50:02 UTC 2021 , Edited by admin on Fri Jun 25 20:50:02 UTC 2021
|
PRIMARY | |||
|
154584814
Created by
admin on Fri Jun 25 20:50:02 UTC 2021 , Edited by admin on Fri Jun 25 20:50:02 UTC 2021
|
PRIMARY | |||
|
C88345
Created by
admin on Fri Jun 25 20:50:02 UTC 2021 , Edited by admin on Fri Jun 25 20:50:02 UTC 2021
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> AGONIST | |||
|
TARGET -> AGONIST |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Class: Antineoplastic; Mechanism of Action: Dopamine receptor agonist, Somatostatin receptor agonist; Highest Development Phases: Discontinued for Acromegaly, Malignant carcinoid syndrome, Neuroendocrine tumours, Pituitary cancer; Most Recent Events: 16 Dec 2010 Discontinued - Preclinical for Pituitary cancer in France (SC), 16 Dec 2010 Discontinued - Preclinical for Neuroendocrine tumours in France (SC), 16 Dec 2010 Discontinued - Phase-II for Carcinoid syndrome in Europe (SC)
|